BioSpace News Archive

System for assessing urinary tract infections at the point of care, and determining optimal antibiotic course, is on track for initial trials in 2020

STERIS plc announced that it will host a conference call to discuss its fiscal 2020 fourth quarter and full year financial results at 10:00 a.m. Eastern Time on Thursday, May 14, 2020.

First Quarter TIBSOVO® Net Revenue of $22.7 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders, announced that it will report its financial results for the first quarter of 2020 on Friday, May 8, 2020 before the opening of the U.S. financial markets.

Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, reported its operating and financial results for the first quarter ended March 31, 2020.

122 Subject, Multicenter, Double-Blind, Randomized, Clinical Trial Finds PoNS Treatment™ Provides Significant Improvement in Balance and Gait Deficits for Individuals Who Have Experienced a Mild-to-Moderate Traumatic Brain Injury

The Montreal Heart Institute Research Center has extended its COLCORONA COVID-19 clinical trial to a third Canadian province being Ontario.

Evogene Ltd., a leading biotechnology company aiming to revolutionize the development of novel products for life-science based industries, announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019 with the U.S. Securities and Exchange Commission..

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that it will release its first quarter 2020 financial results on Thursday, May 7, after the close of the U.S. financial markets..

Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that it will report its first quarter 2020 financial results on Thursday, May 7, 2020.